Mutual of America Capital Management LLC Invests $3.04 Million in Vaxcyte, Inc. (NASDAQ:PCVX)

Mutual of America Capital Management LLC acquired a new position in Vaxcyte, Inc. (NASDAQ:PCVX) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 48,330 shares of the company’s stock, valued at approximately $3,035,000.

Several other institutional investors have also recently modified their holdings of PCVX. Russell Investments Group Ltd. purchased a new position in shares of Vaxcyte in the first quarter worth about $30,000. Avior Wealth Management LLC purchased a new position in shares of Vaxcyte in the third quarter worth about $178,000. Wells Fargo & Company MN raised its stake in shares of Vaxcyte by 162.5% in the fourth quarter. Wells Fargo & Company MN now owns 3,961 shares of the company’s stock worth $190,000 after purchasing an additional 2,452 shares during the last quarter. Osaic Holdings Inc. raised its stake in shares of Vaxcyte by 59.9% in the second quarter. Osaic Holdings Inc. now owns 4,073 shares of the company’s stock worth $200,000 after purchasing an additional 1,526 shares during the last quarter. Finally, Creative Planning purchased a new position in shares of Vaxcyte in the fourth quarter worth about $205,000. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, SVP Elvia Cowan sold 11,678 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $74.08, for a total value of $865,106.24. Following the transaction, the senior vice president now owns 12,480 shares in the company, valued at $924,518.40. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, SVP Mikhail Eydelman sold 1,667 shares of Vaxcyte stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $73.87, for a total transaction of $123,141.29. Following the transaction, the senior vice president now owns 20,710 shares in the company, valued at $1,529,847.70. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Elvia Cowan sold 11,678 shares of Vaxcyte stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $74.08, for a total value of $865,106.24. Following the transaction, the senior vice president now owns 12,480 shares in the company, valued at approximately $924,518.40. The disclosure for this sale can be found here. Insiders have sold a total of 101,577 shares of company stock worth $6,940,475 over the last quarter. 3.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

PCVX has been the topic of several analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $95.00 target price on shares of Vaxcyte in a report on Wednesday, April 10th. Bank of America raised their target price on Vaxcyte from $67.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, January 2nd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a report on Friday, January 12th. Four analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $78.50.

Vaxcyte Price Performance

NASDAQ PCVX opened at $60.62 on Friday. The company has a market cap of $6.59 billion, a PE ratio of -14.68 and a beta of 0.89. The stock’s 50 day simple moving average is $69.67 and its 200-day simple moving average is $60.85. Vaxcyte, Inc. has a 1-year low of $41.57 and a 1-year high of $82.04.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Tuesday, February 27th. The company reported ($1.82) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.93). During the same quarter last year, the firm posted ($0.73) earnings per share. On average, equities research analysts anticipate that Vaxcyte, Inc. will post -4.18 EPS for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.